ALCGM.PA

Full House

Cegedim SA · Healthcare · France · $133M cap · $67K/day traded

EUR 8.85 +1.1% · close 20 Nov · scored 21 Nov

Score up 1.1 since 20 Nov.

Full House: Strong business, sensible price, and the market agrees.

91
Score
Get score and insider alerts
Quality
52
Value
85
Momentum
59

As of 21 Nov 2026, the MoatMap Score for Cegedim SA (ALCGM.PA) is 91/100, ranked against 25,000+ stocks in 38 markets (Quality 52, Value 85, Momentum 59, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
9.2x
peers 23.4x
ROE
4.3%
peers -69.7%
D/E
1.1x
peers 0.5x
Dividend %
—
trailing yield

ABOUT CEGEDIM SA

Read

Cegedim SA operates as a technology and services company in the field of digital data flow management for healthcare and B2B ecosystem in France, rest of Europe, the Middle East, Africa, and internationally.

FINANCIAL SUMMARY (EUR)

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Income and shares
Revenue524.7M555.2M616.0M654.5M649.2M5.5%651.5M661.1M684.1M2.7%
Net margin5.0%2.5%-1.2%-2.2%1.4%-3.6 pts————
EPS (EUR)—1.00-0.50-1.100.70-11.2%0.960.831.2634.4%
Share count—13.6M13.6M13.7M13.7M0.3%13.7M———
Balance sheet
Debt—91.8M93.5M91.8M93.8M0.7%322.2M———
Equity—285.2M276.2M264.3M274.7M-1.2%————
Debt/equity—0.3x0.3x0.3x0.3x0.0x————
Cash flow
Op. cash flow—86.5M97.9M101.8M152.2M20.7%154.5M———
Cash flow margin—15.6%15.9%15.6%23.4%+7.8 pts23.7%———
Investing CF—-20.2M-75.3M-111.3M-68.2M—————
Financing CF—-33.9M-31.1M13.1M-41.0M—————
PRICE (1Y) · EUR-18.1%
8.89.39.810.310.812 Oct2 Nov20 Nov
SMA 50SMA 200

Price checkFinding a floorExperimental

No new 52-week low for 34 weeks, 4% above that low, but not back above a rising 50-day average.

The Momentum score still reads 59: it looks back six months, so it has not caught up with this fall.

SwingsAverage

Calmer than 65% of stocks we rank over the past year (volatility 34% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor (this stock): It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
EUR 8.85
RSI (14)
27.7
52-Week Range-42.2% from high
Low EUR 8.50High EUR 15.30

SCORE BREAKDOWN

Quality
52
ROIC
4.7%53.5
ROE
4.3%53.1
GP/Assets
27.0%59.7
Op. Margin
6.0%55.3
FCF/Assets
7.8%80.3
Piotroski
668.8
Int. Cover
1.5x40.1
D/E Ratio
1.08x12.2
Current Ratio
0.95x9.5
Value
85
P/E (TTM)
9.2x88.1
EV/EBITDA
6.4x84.2
P/FCF
1.5x98.6
P/B
0.4x95.8
P/S
0.2x97.6
Div Yield
—N/A
Momentum
59
52W High %
58%45.7
RS 6M
-23%26.9
SMA 50/200
0.95x49.9
EPS Rev 4W
+20.9%95.3
EPS Rev 12W
—N/A
EPS Improve
+88%72.8
Q Growth
362%95.2

FUNDAMENTALS

Market Cap
$133M
P/E (Forward)
4.9x
Gross Margin
42.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALCGM.PA are excluded.

TickerCompanyMkt CapScore
ALCGM.PACegedim SA(you)$133M91
EQS.PAEquasens Société anonyme$433M84
BLC.PABastide Le Confort Médical SA$153M92
ALERS.PAEurobio Scientific Société anonyme$292M85
BOI.PABoiron SA$359M89
LNA.PALNA Santé SA$287M78
VETO.PAVetoquinol SA$1.1B95
EAPI.PAEuroapi S.A.$67M44
GBT.PAGuerbet SA$90M32
VIRP.PAVirbac SA$3.1B87

Peer medians: ROE -69.7% · P/E 23.4x · Gross margin 69.3%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Cegedim SA (ALCGM.PA): Stock Score Summary

Cegedim SA (ALCGM.PA) has a MoatMap Score of 91/100 based on Quality (52/100), Value (85/100), and Momentum (59/100) factor scores.

Cegedim SA operates as a technology and services company in the field of digital data flow management for healthcare and B2B ecosystem in France, rest of Europe, the Middle East, Africa, and internationally.

Director dealings

From 19 Feb 2026 to 20 Nov 2026, MoatMap's records hold no sales and 3 purchases of Cegedim SA (ALCGM.PA) shares by its directors. The largest: FCB SAS bought 74,537 shares at EUR 12.00 on 24 Apr 2026 (about EUR 894K).

  • 27 Apr 2026: FCB SAS bought 751 shares at EUR 11.99 (about EUR 9K)
  • 24 Apr 2026: FCB SAS bought 74,537 shares at EUR 12.00 (about EUR 894K)
  • 14 Apr 2026: FCB SAS bought 500 shares at EUR 12.00 (about EUR 6K)
ALCGM.PA insider filings, last 180 days

Key Financial Metrics

PriceEUR 8.85
Market Cap$133M
P/E (TTM)9.22
P/E (Forward)4.90
Price/Book0.43
Return on Equity4.3%
Return on Invested Capital4.7%
Debt/Equity1.08x
Gross Margin42.3%
Operating Margin6.0%
Revenue Growth0.7%
Free Cash Flow$88M

Cegedim SA operates in the Health Information Services industry, part of the Healthcare sector (France).

Frequently Asked Questions

What is Cegedim SA’s (ALCGM.PA) MoatMap Score?
The MoatMap Score for Cegedim SA (ALCGM.PA) is 91/100. It is a composite of Quality (52), Value (85), and Momentum (59), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Cegedim SA have an economic moat?
Cegedim SA (ALCGM.PA) has a Quality factor score of 52/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Cegedim SA in?
Cegedim SA (ALCGM.PA) operates in the Healthcare sector, specifically the Health Information Services industry (France).